Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Glaucoma Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Developing Drugs for the Market Entry

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

18 May, 2023, 15:00 GMT

Share this article

Share toX

Share this article

Share toX

The glaucoma pipeline and clinical trial analysis report delivers important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis. 

LAS VEGAS, May 18, 2023 /PRNewswire/ -- DelveInsight's 'Glaucoma Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline glaucoma drugs in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the glaucoma competitive domain.

Key Takeaways from the Glaucoma Competitive Landscape Report

  • Over 45+ glaucoma companies are evaluating 50+ glaucoma drugs in various stages of development, and their anticipated acceptance in the glaucoma market would significantly increase market revenue. 
  • Key glaucoma companies such as Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Ocuphire Pharma, HK inno.N, VivaVision Biotech, Qlaris Bio, Future Medicine, PolyActiva Pty Ltd, Theratocular Biotek, Whitecap Biosciences, JeniVision, AbbVie, Noveome Biotherapeutics, and others are evaluating new glaucoma drugs to improve the treatment landscape.
  • Promising glaucoma pipeline therapies such as DE-130A, PDP-716, NCX 470, PHP-201, Citicoline, TRS01, TC-002, T4032, Bremen, POLAT 001, Nyxol, IN-A010, VVN539, QLS-101, FM 101, PA5108, TO-O-1001, WB-007, JV-GL1, AGN-193408 SR, ST266, and others are under different phases of glaucoma clinical trials.
  • In December 2022, Visiox Pharma announced that it had received notification from the US Food and Drug Administration (FDA) that the agency had completed its filing review and accepted for filing the New Drug Application (NDA) for PDP-716 (0.35% brimonidine tartrate) for the treatment of glaucoma.
  • In October 2022, Essex Biotechnology Ltd announced that its wholly-owned subsidiary Essex Bioinvestment Ltd had secured (i) a patent and know-how license agreement; and (ii) a patent assignment deed in relation to SkQ1, an active pharmaceutical ingredient from Mitotech S.A. Under these Agreements, Mitotech grants Essex Bioinvestment worldwide rights (excluding Armenia, Belarus, Kazakhstan, Kyrgyzstan, and Russia) and interests in SkQ1, transferable and irrevocable, in the field of ophthalmology exclusively.
  • On October 6, 2022, Santen Pharmaceutical announced that the European Medicines Agency (EMA) had accepted the Santen filing for reviewing the marketing authorization application for the use of STN1013001 for the lowering of intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. The marketing authorization application is based on a clinical package that includes positive results from a Phase III clinical trial conducted in Europe and Asia – a non-inferiority trial of STN1013001.
  • In September 2022, TearClear announced that the company's lead product, TC-002 (latanoprost ophthalmic solution 0.005%), met the primary and all secondary endpoints in the CLEAR Phase III pivotal trial. With these results, TearClear plans to file a New Drug Application (NDA) with the US Food and Drug Administration (FDA) in the first quarter of 2023.
  • In May 2022, Qlaris Bio, Inc., announced results from QC-201, a first-in-human, Phase 2 clinical trial of QLS-101, the Company's investigational therapy for lowering intraocular pressure (IOP) in the treatment of glaucoma. Study findings demonstrated a favorable safety and tolerability profile for QLS-101, including no evidence of hyperemia (eye redness) and a positive efficacy signal, in patients with primary open-angle glaucoma (POAG) or ocular hypertension.
  • In December 2021, Sun Pharma Advanced Research Company Ltd. announced that it had entered into an agreement with Visiox Pharma LLC (Visiox) to grant exclusive worldwide rights (except for India and Greater China) for the development and commercialization of PDP-716 and SDN-037. Under the terms of the license agreement, SPARC received an upfront payment, milestone payments, and royalties on sales, in addition to 10% equity* in Visiox.

Request a sample and discover the recent advances in glaucoma treatment drugs @ Glaucoma Competitive Landscape Report

Glaucoma Overview

Glaucoma refers to a group of disorders characterized by distinctive cupping of the optic disc and associated visual field abnormalities caused by retinal ganglion cell death. It is a progressive disorder that is the leading cause of irreversible blindness in the globe. Open-angle glaucoma and narrow-angle glaucoma/angle-closure glaucoma are the two major types of glaucoma. In both cases, the "angle" refers to the drainage angle within the eye, which governs the outflow of the watery fluid produced within the eye.

Most people with glaucoma do not notice symptoms until they lose their vision. As glaucoma destroys the optic nerve fibers, tiny blind patches may form. These specks typically appear on the side or in the peripheral vision. Many people do not detect blind spots until considerable optic nerve damage has occurred. Blindness can occur if the entire nerve is damaged. Although there is no cure for glaucoma, early glaucoma treatment can frequently prevent more damage and preserve vision. Glaucoma is treated with various methods, including medications (typically eye drops), laser treatment, and surgery.

Find out more about glaucoma treatment drugs @ Drugs for Glaucoma Treatment

Glaucoma Pipeline Analysis: Drug Profile

NCX 470: Nicox Ophthalmics

Nicox Ophthalmics is actively developing NCX 470, a novel, second-generation nitric oxide (NO)-donating prostaglandin analog. NCX-470 may benefit glaucoma patients by a mechanism other than IOP reduction, most notably by improving ocular perfusion. Preliminary research indicates that if approved, NCX-470's dual mechanistic approach (nitric oxide donation and prostaglandin F2 activity) could make it the most effective single-agent glaucoma therapy in terms of IOP-lowering efficacy. The medication is currently in Phase III clinical trials for the treatment of open-angle glaucoma or ocular hypertension.

TRS01: Tarsier Pharma

TRS01, developed by Tarsier, is a potent, fast-acting immunomodulator administered as eye drops for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma, which is considered an end-stage uveitis condition. Once a patient has uveitis plus glaucoma (uveitic glaucoma), the only effective therapy for active inflammation, steroids, should be avoided due to the negative effects of hastening glaucoma and vision loss. TRS01 could thus become the standard of care for uveitic glaucoma. TRS01, an eye drop formulation of TRS, is being developed to treat the signs and symptoms of active uveitis in patients with uveitic glaucoma. TRS01 is now undergoing Phase III testing.

A snapshot of the Glaucoma Pipeline Drugs mentioned in the report:

Glaucoma Drugs

Company

Phase 

MoA

Latanoprost emulsion 

Santen SAS

Preregistration

Prostaglandin F2 alpha agonists

Brimonidine ophthalmic suspension 

Sun Pharma Advanced Research Company

Preregistration

Alpha 2 adrenergic receptor agonists

NCX 470

Nicox Ophthalmics

Phase III

Nitric oxide donors

TRS01

Tarsier Pharma

Phase III

Carbonic anhydrase inhibitors; Prostaglandin F2 alpha agonists

QLS-101

Qlaris Bio

Phase II

KATP channel modulators

PHP-201

Amakem

Phase II

Rho-associated kinase inhibitors

Latanoprost controlled release 

Peregrine Ophthalmic

Phase II

Prostaglandin F2 alpha agonists

Phentolamine 

Ocuphire Pharma

Phase II

Alpha 1 adrenergic receptor antagonists; Alpha 2 adrenergic receptor antagonists

ST266

Noveome Biotherapeutics

Phase I

Bone development modulators; Neuron modulators; Paracrine communication modulators; Proto oncogene protein c akt modulators; SIRT1 protein stimulants

Learn more about the emerging glaucoma pipeline therapies @ Glaucoma Clinical Trials

Scope of the Glaucoma Competitive Landscape Report 

  • Coverage: Global 
  • Key Glaucoma Companies: Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Ocuphire Pharma, HK inno.N, VivaVision Biotech, Qlaris Bio, Future Medicine, PolyActiva Pty Ltd, Theratocular Biotek, Whitecap Biosciences, JeniVision, AbbVie, Noveome Biotherapeutics, and others
  • Key Glaucoma Pipeline Therapies: DE-130A, PDP-716, NCX 470, PHP-201, Citicoline, TRS01, TC-002, T4032, Bremen, POLAT 001, Nyxol, IN-A010, VVN539, QLS-101, FM 101, PA5108, TO-O-1001, WB-007, JV-GL1, AGN-193408 SR, ST266, and others
  • Company Analysis, Therapeutic Assessment, Pipeline Assessment, Inactive drugs assessment, Unmet Needs

Dive deep into rich insights for new drugs for glaucoma treatment, visit @ Glaucoma Drugs

Table of Contents

1.

Glaucoma Pipeline Report Introduction

2.

Glaucoma Pipeline Report Executive Summary

3.

Glaucoma Pipeline: Overview

4.

Glaucoma Marketed Drugs 

4.1.

DURYSTA: Allergan

5.

Glaucoma Clinical Trial Therapeutics

6.

Glaucoma Pipeline: Late-Stage Products (Pre-registration)

7.

Glaucoma Pipeline: Late-Stage Products (Phase III)

7.1.

NCX 470: Nicox Ophthalmics

8.

Glaucoma Pipeline: Mid-Stage Products (Phase II)

8.1.

QLS-101: Qlaris Bio

9.

Glaucoma Pipeline: Early-Stage Products (Phase I)

9.1.

ST266: Noveome Biotherapeutics

10.

Glaucoma Pipeline Therapeutics Assessment

11.

Inactive Products in the Glaucoma Pipeline

12.

Company-University Collaborations (Licensing/Partnering) Analysis

13.

Unmet Needs

14.

Glaucoma Market Drivers and Barriers

15.

Appendix

For further information on the glaucoma pipeline therapeutics, reach out @ Glaucoma Treatment Drugs

Related Reports

Glaucoma Market

Glaucoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glaucoma companies, including Novaliq GmbH, Kowa, D. Western Therapeutics Institute, Sun Pharma Advanced Research Company, among others.

Glaucoma Epidemiology Forecast

Glaucoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted glaucoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Open Angle Glaucoma Market

Open Angle Glaucoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key open angle glaucoma companies, including AbbVie, PolyActiva, SALVAT, among others.

Open Angle Glaucoma Pipeline

Open Angle Glaucoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key open angle glaucoma companies, including AbbVie, PolyActiva, SALVAT, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Contact Us
Shruti Thakur 
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

DelveInsight's Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, sleep apnea emerging drugs,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.